As of June 30, 2026, Kraig Biocraft Laboratories, Inc. carries a market capitalization of 113.40M, placing it among publicly traded companies globally. Its enterprise value stands at 116.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 113.40M |
| Enterprise Value | 116.93M |
As of June 30, 2026, Kraig Biocraft Laboratories, Inc. has 1.11B shares outstanding.
| Shares Outstanding | 1.11B |
These figures are as of June 30, 2026.
| PB Ratio | -9.46 |
| P/TBV Ratio | -9.46 |
| P/FCF Ratio | -53.20 |
| P/OCF Ratio | -54.36 |
As of June 30, 2026, Kraig Biocraft Laboratories, Inc. maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -24.97, indicating conservative leverage, while an interest coverage ratio of -6.22 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.33 |
| Quick Ratio | 0.31 |
| Debt / Equity | -24.97 |
| Debt / EBITDA | -0.46 |
| Interest Coverage | -6.22 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -141.54, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.50, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -141.54 |
| Employee Count | 21.50 |
As of the close on November 16, 2026, Kraig Biocraft Laboratories, Inc.'s stock has declined approximately 3.04% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.11.
| 52-Week Price Change | -3.04% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.11 |
Over the twelve months ended June 30, 2026, Kraig Biocraft Laboratories, Inc. generated - - in revenue and converted that into -4.15M in net income, yielding earnings per share of 0.00. EBITDA reached -3.66M, while operating income came in at -3.69M.
| Operating Income | -3.69M |
| Pretax Income | -4.15M |
| Net Income | -4.15M |
| EBITDA | -3.66M |
| EBIT | -3.69M |
As of June 30, 2026, Kraig Biocraft Laboratories, Inc. holds 3.39M in cash and equivalents against 1.69M in total debt, resulting in a net debt position of -1.90M. Total book value stands at -11.99M, with working capital of -7.33M providing operational flexibility.
| Cash & Cash Equivalents | 3.39M |
| Total Debt | 1.69M |
| Net Debt | -1.90M |
| Equity (Book Value) | -11.99M |
| Book Value Per Share | -0.01 |
| Working Capital | -7.33M |
Kraig Biocraft Laboratories, Inc. produced -2.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -44,336.00 in capital expenditures, free cash flow totaled -2.08M - equivalent to 0.00 per share.
| Operating Cash Flow | -2.04M |
| Capital Expenditures | -44,336.00 |
| Free Cash Flow | -2.08M |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.88: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.87, meaning Kraig Biocraft Laboratories, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -3.87 |
| FCF Yield | -1.88 |
Kraig Biocraft Laboratories, Inc.'s most recent stock split took place on May 28, 2009 with a 1:10 split ratio.
| Last Split Date | 5/28/2009 |
| Split Ratio | 1:10 |
As of June 30, 2026, Kraig Biocraft Laboratories, Inc. has an Altman Z-Score of -17.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.93 |